NCT03223103View on ClinicalTrials.gov

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

May 12, 2029

Study Completion Date

May 12, 2029

Conditions
Glioblastoma
Interventions
DRUG

Poly-ICLC

Poly-ICLC 100mcg per peptide per dose

DEVICE

Tumor Treating Fields

an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM

BIOLOGICAL

Peptides

synthetic long peptides (SLP) as vaccine substrate

Trial Locations (1)

10461

Albert Einstein College of Medicine, The Bronx

All Listed Sponsors
collaborator

NovoCure Ltd.

INDUSTRY

lead

Adilia Hormigo

OTHER